AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior listings of claims in this application.

Claims 1-19 (Canceled)

Claim 20 (Currently Amended): A method of treating premenstrual syndrome in a patient in need thereof who failed to respond to initial treatment with a selective serotonin reuptake inhibitor other than escitalopram comprising administering a pharmaceutically effective amount of escitalopram or a pharmaceutically acceptable salt thereof ~~as the sole active ingredient~~ to the patient.

Claim 21 (Previously Presented): The method of claim 20, wherein the pharmaceutically effective amount is a daily dose of 10 mg or less of escitalopram or a pharmaceutically acceptable salt thereof to the patient.

Claim 22 (Previously Presented): The method of claim 20, wherein the daily dose is 10 mg of escitalopram or a pharmaceutically acceptable salt thereof.

Claim 23 (Previously Presented): The method of claim 21, wherein the daily dose is 7.5 mg or less of escitalopram or a pharmaceutically acceptable salt thereof.

Claim 24 (Previously Presented): The method of claim 23, wherein the daily dose is 7.5 mg of escitalopram or a pharmaceutically acceptable salt thereof.

Claim 25 (Previously Presented): The method of claim 23, wherein the daily dose is 5 mg of escitalopram or a pharmaceutically acceptable salt thereof.

Claim 26 (Previously Presented): The method of claim 20, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 27 (Previously Presented): The method of claim 21, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 28 (Previously Presented): The method of claim 22, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 29 (Previously Presented): The method of claim 23, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 30 (Previously Presented): The method of claim 24, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 31 (Previously Presented): The method of claim 25, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 32 (Previously Presented): The method of claim 26, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 33 (Previously Presented): The method of claim 27, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 34 (Previously Presented): The method of claim 28, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 35 (Previously Presented): The method of claim 29, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 36 (Previously Presented): The method of claim 30, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 37 (Previously Presented): The method of claim 31, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 38 (New): The method of claim 20, wherein the method comprises administering a pharmaceutically effective amount of escitalopram or a pharmaceutically acceptable salt thereof as the sole active ingredient to the patient.